Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Palliative Care
Published in: BMC Palliative Care 1/2018

Open Access 01-12-2018 | Research article

Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions

Authors: Lucas Pieper, Julia Wager, Boris Zernikow

Published in: BMC Palliative Care | Issue 1/2018

Login to get access

Abstract

Background

Respiratory distress is one of the most common and frightening symptoms of children with life-limiting conditions. Because treatment of the underlying cause is frequently impossible or insufficient, in many children, symptomatic treatment is warranted. The purpose of this study was to describe the circumstances of the use of intranasal fentanyl in an acute attack of respiratory distress (AARD) in children receiving palliative care, as well as to describe outcomes and adverse events after its use.

Methods

Children and adolescents treated in a pediatric palliative unit or attended by a specialized home care team between 2010 and 2016 were included in this study. A retrospective chart review was conducted of those who were treated with intranasal fentanyl for an AARD.

Results

During the study period 16 children (0.5–18.6 years) with various life-limiting conditions were treated with intranasal fentanyl for AARD. In total, 70 AARDs were analyzed. In 74% of all AARDs, a single dose of intranasal fentanyl was used. Frequent causes for an AARD were excessive secretions and acute respiratory infection. The median starting dose of intranasal fentanyl was 1.5 μg/kg body weight. Labored breathing (96%), tachypnea (79%) and related suffering (97%) improved after treatment. An adverse event occurred in one child.

Conclusions

Intranasal fentanyl may be a safe and effective medication for the treatment of acute attacks of respiratory distress in children with life-limiting conditions. However, prospective studies with larger sample sizes and a control group are needed to validate these findings.
Literature
1.
Craig F, Henderson EM, Bluebond-Langner M. Management of respiratory symptoms in paediatric palliative care. Curr. Opin. Support. Palliat. Care. 2015;9(3):217–26.CrossRefPubMed
2.
Blume ED, Balkin EM, Aiyagari R, Ziniel S, Beke DM, Thiagarajan R, Taylor L, Kulik T, Pituch K, Wolfe J. Parental perspectives on suffering and quality of life at end-of-life in children with advanced heart disease: an exploratory study*. Pediatr. Crit. Care Med. 2014;15(4):336–42.CrossRefPubMed
3.
von Lutzau P, Otto M, Hechler T, Metzing S, Wolfe J, Zernikow B. Children dying from cancer: parents' perspectives on symptoms, quality of life, characteristics of death, and end-of-life decisions. J Palliat Care 2012, 28(4):274–281.
4.
Hechler T, Blankenburg M, Friedrichsdorf SJ, Garske D, Hubner B, Menke A, Wamsler C, Wolfe J, Zernikow B. Parents' perspective on symptoms, quality of life, characteristics of death and end-of-life decisions for children dying from cancer. Klinische Padiatrie. 2008;220(3):166–74.CrossRefPubMed
5.
Wolfe J, Hammel JF, Edwards KE, Duncan J, Comeau M, Breyer J, Aldridge SA, Grier HE, Berde C, Dussel V, et al. Easing of suffering in children with cancer at the end of life: is care changing? J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008;26(10):1717–23.CrossRef
6.
Wolfe J, Grier HE, Klar N, Levin SB, Ellenbogen JM, Salem-Schatz S, Emanuel EJ, Weeks JC. Symptoms and suffering at the end of life in children with cancer. N Engl J Med. 2000;342(5):326–33.CrossRefPubMed
7.
Theunissen JM, Hoogerbrugge PM, van Achterberg T, Prins JB, Vernooij-Dassen MJ, van den Ende CH. Symptoms in the palliative phase of children with cancer. Pediatr Blood Cancer. 2007;49(2):160–5.CrossRefPubMed
8.
Schindera C, Tomlinson D, Bartels U, Gillmeister B, Alli A, Sung L. Predictors of symptoms and site of death in pediatric palliative patients with cancer at end of life. Am. J. Hosp. Palliat. Care. 2013;31(5):548–52.CrossRefPubMed
9.
Gormley PK, Colreavy MP, Patil N, Woods AE. Congenital vascular anomalies and persistent respiratory symptoms in children. Int J Pediatr Otorhinolaryngol. 1999;51(1):23–31.CrossRefPubMed
10.
11.
Hunt AM. A survey of signs, symptoms and symptom control in 30 terminally ill children. Dev Med Child Neurol. 1990;32(4):341–6.CrossRefPubMed
12.
Drake R, Frost J, Collins JJ. The symptoms of dying children. J Pain Symptom Manag. 2003;26(1):594–603.CrossRef
13.
Monnier P, Lang F, Savary M. Partial cricotracheal resection for pediatric subglottic stenosis: a single institution's experience in 60 cases. Eur. Arch. Otorhinolaryngol. 2003;260(6):295–7.CrossRefPubMed
14.
Garske D, Schmidt P, Hasan C, Wager J, Zernikow B. Palliativversorgung auf der pädiatrischen Palliativstation “Lichtblicke” – Eine retrospektive Studie. Zeitschrift für Palliativmedizin. 2016;17(06):302–7.CrossRef
15.
Collins JJ, Byrnes ME, Dunkel IJ, Lapin J, Nadel T, Thaler HT, Polyak T, Rapkin B, Portenoy RK. The measurement of symptoms in children with cancer. J Pain Symptom Manag. 2000;19(5):363–77.CrossRef
16.
Pieper L, Zernikow B, Drake R, Frosch M, Printz M, Wager J. Dyspnea in children with life-threatening and life-limiting complex chronic conditions. J Palliat Med. 2018;
17.
American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999;159(1):321–40.CrossRef
18.
19.
Leach RM. Palliative care in non-malignant, end-stage respiratory disease. In: Hanks G, Cherny NI, Christakis NA, Fallon M, Kaasa S, Portenoy RK, editors. Oxford textbook of palliative medicine. Edn. New York, NY: Oxford University Press; 2010. p. 1231–67.
20.
Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol. 2009;167(1):53–60.CrossRefPubMed
21.
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52.CrossRefPubMedPubMedCentral
22.
23.
Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. The Cochrane database of systematic reviews 2008(2):Cd005623.
24.
Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–44.CrossRefPubMedPubMedCentral
25.
Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ (Clinical research ed). 2003;327(7414):523–8.CrossRef
26.
Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. J Pain Symptom Manag. 2008;36(6):e3–6.CrossRef
27.
Sitte T. Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report. Wien. Med. Wochenschr (1946). 2009;159(23–24):566–70.CrossRef
28.
Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012, 134(3):366–379.
29.
Crellin D, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 microg/mL) administered intranasally have analgesic efficacy? Emerg. Med. Australas. : EMA. 2010;22(1):62–7.PubMed
30.
Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet. Pain practice : the official journal of World Institute of Pain. 2007;7(4):324–31.CrossRef
31.
Nave R, Schmitt H, Popper L. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects. Drug delivery. 2013;20(5):216–23.CrossRefPubMed
32.
Mudd S. Intranasal fentanyl for pain management in children: a systematic review of the literature. J. Pediatr. Health Care. 2011;25(5):316–22.CrossRefPubMed
33.
Murphy A, O'Sullivan R, Wakai A, Grant TS, Barrett MJ, Cronin J, McCoy SC, Hom J, Kandamany N. Intranasal fentanyl for the management of acute pain in children. The Cochrane database of systematic reviews 2014(10):Cd009942.
34.
Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011;11(8):1197–216.CrossRefPubMed
35.
Simon ST, Koskeroglu P, Gaertner J, Voltz R. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manag. 2013;46(6):874–86.CrossRef
36.
Bausewein C, Simon ST. Inhaled nebulized and intranasal opioids for the relief of breathlessness. Curr. Opin. Support. Palliat. Care. 2014;8(3):208–12.CrossRefPubMed
37.
Harlos MS, Stenekes S, Lambert D, Hohl C, Chochinov HM. Intranasal fentanyl in the palliative care of newborns and infants. J Pain Symptom Manag. 2013;46(2):265–74.CrossRef
38.
Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration; international review of thoracic diseases. 2004;71(6):646–9.CrossRefPubMed
39.
Bausewein C. Management of refractory breathlessness in patients with advanced disease. Internist. 2016;57(10):978–82.CrossRefPubMed
40.
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.CrossRef
41.
Alt-Epping B, Staritz AE, Simon ST, Altfelder N, Hotz T, Lindena G, Nauck F. What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. J Palliat Med. 2012;15(9):971–7.CrossRefPubMed
42.
43.
Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP. Dyspnea review for the palliative care professional: assessment, burdens, and etiologies. J Palliat Med. 2011;14(10):1167–72.CrossRefPubMedPubMedCentral
44.
Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emergency medicine (Fremantle, WA). 2002;14(3):275–80.CrossRef
45.
Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg. Med. Australas. : EMA. 2008;20(6):515–20.PubMed
46.
Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007;49(3):335–40.CrossRefPubMed
47.
Finkel JC, Cohen IT, Hannallah RS, Patel KM, Kim MS, Hummer KA, Choi SS, Pena M, Schreiber SB, Zalzal G. The effect of intranasal fentanyl on the emergence characteristics after sevoflurane anesthesia in children undergoing surgery for bilateral myringotomy tube placement. Anesth Analg. 2001;92(5):1164–8.CrossRefPubMed
48.
Galinkin JL, Fazi LM, Cuy RM, Chiavacci RM, Kurth CD, Shah UK, Jacobs IN, Watcha MF. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology. 2000;93(6):1378–83.CrossRefPubMed
49.
Holdgate A, Cao A, Lo KM. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. Acad Emerg Med Off J Soc Acad Emerg Med. 2010;17(2):214–7.CrossRef
50.
Manjushree R, Lahiri A, Ghosh BR, Laha A, Handa K. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can. J. Anaesth. 2002;49(2):190–3.CrossRefPubMed
51.
Younge PA, Nicol MF, Kendall JM, Harrington AP. A prospective randomized pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg Med. 1999;11:90–4.CrossRef
Metadata
Title
Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions
Authors
Lucas Pieper
Julia Wager
Boris Zernikow
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Palliative Care / Issue 1/2018
Electronic ISSN: 1472-684X
DOI
https://doi.org/10.1186/s12904-018-0361-x

Other articles of this Issue 1/2018

BMC Palliative Care 1/2018 Go to the issue

Study protocol

Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study)

Research article

Self-competence in death work among health and social care workers: a region-wide survey in Hong Kong

Research article

Key features of palliative care service delivery to Indigenous peoples in Australia, New Zealand, Canada and the United States: a comprehensive review

Research article

Fractionated palliative thoracic radiotherapy in non-small cell lung cancer – futile or worth-while?

Research article

Striving for a balance between leading and following the patient and family – nurses’ strategies to facilitate the transition from life-prolonging care to palliative care: an interview study

Research article

Using co-design to develop an intervention to improve communication about the heart failure trajectory and end-of-life care